Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL6990432 | 0.93 | DRD3 (0.44) | DRD3IDO1CYP19A1ADRA2AHTR1A | |
| SCHEMBL599314 | 0.84 | CYP19A1 (0.54) | CYP19A1HTR1ASIGMAR1 | |
| SCHEMBL3916886 | 0.80 | FYN (0.57) | DRD3IDO1CYP19A1ADRA2AHTR1A | |
| SCHEMBL18322481 | 0.80 | PNMT (0.41) | DRD3 | |
| Hydrochloric Acid SCHEMBL18706948 | 0.78 | PNMT (0.40) | DRD3IDO1 | |
| SCHEMBL27520710 | 0.75 | HTR7 (0.51) | HTR1A | |
| SCHEMBL13572976 | 0.75 | SIGMAR1 (0.52) | HTR1ASIGMAR1 | |
| SCHEMBL13291929 | 0.75 | DRD3 (0.48) | DRD3CYP19A1ADRA2AHTR1AHTR2A | |
| SCHEMBL32686719 | 0.75 | DRD2 (0.48) | DRD3HTR1A | |
| SCHEMBL13572973 | 0.75 | SIGMAR1 (0.52) | HTR1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913902-B2 | Production of high energy-dense liquid hydrocarbon from low energy-dense aqueous solutions of oxygen containing organic compound(s) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2021-02-09 | — | — | US | claimed |
| US-20200056099-A1 | PRODUCTION OF HIGH ENERGY-DENSE LIQUID HYDROCARBON FROM LOW ENERGY-DENSE AQUEOUS SOLUTIONS OF OXYGEN CONTAINING ORGANIC COMPOUND(S) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2020-02-20 | — | — | US | claimed |
| US-20260080976-A1 | SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES | PURDUE RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | disclosed |
| US-12414937-B2 | Local and regional anesthesia and analgesia | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| CN-115768740-A | Process for preparing indene acrolein derivative | 弗门尼舍有限公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-3904354-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2021-11-03 | — | — | EP | disclosed |
| US-10913902-B2 | Production of high energy-dense liquid hydrocarbon from low energy-dense aqueous solutions of oxygen containing organic compound(s) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2021020429-A1 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | 大正製薬株式会社 | 2021-02-04 | — | — | WO | disclosed |
| US-20200056099-A1 | PRODUCTION OF HIGH ENERGY-DENSE LIQUID HYDROCARBON FROM LOW ENERGY-DENSE AQUEOUS SOLUTIONS OF OXYGEN CONTAINING ORGANIC COMPOUND(S) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2020-02-20 | — | — | US | disclosed |
| EP-1888502-B1 | CATALYTIC SCRIABINE REACTION | FIRMENICH & CIE (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-1675824-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | Oy Juvantia Pharma Ltd (FI) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005056520-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 1 (SSTR1) ACTIVE COMPOUNDS AND THEIR USE IN THERAPY | OY JUVANTIA PHARMA LTD (FI) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005033068-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033069-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |
| CN-1113874-C | Benzocycloalkylazolethione derivatives | SYNTEX INC (US) | 2003-07-09 | — | — | CN | disclosed |
| CN-1151735-A | Benzocycloalkylazolethione derivatives | SYNTEX INC (US) | 1997-06-11 | — | — | CN | disclosed |
| US-4182896-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | SOCIETE HEXACHIMIE (FR) | 1980-01-08 | — | — | US | disclosed |
| US-4166131-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, ANTIARTHRITIC AGENT | HEXACHIMIE SOCIETE ANONYME (FR) | 1979-08-28 | — | — | US | disclosed |
| US-3939095-A | PHENYLINDANES, ADDITION COPOLYMERS | BADISCHE ANILIN- & SODA-FABRIK AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | DRD3 4705/4885IDO1 1263/4885CYP19A1 3649/4885 |
| US-20260080976-A1 | SYSTEM AND METHODS FOR GENERATION OF FRAGMENT MODULE LIBRARIES FOR LEAD OPTIMIZATION OF PHARMACEUTICALLY ACTIVE MOLECULES | BACE2, ADAM33, SET | DRD3 300/4885IDO1 3262/4885CYP19A1 1689/4885 |
| US-12414937-B2 | Local and regional anesthesia and analgesia | OPRL1, OPRK1, OPRM1 | DRD3 622/4885IDO1 1093/4885CYP19A1 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.